drugset / Trial / NCT05874037
Fluvoxamine for Long COVID-19
Phase 2/3
Completed
191 enrolled
Washington University School of Medicine
BJH Townley Fund · collabBalvi COVID Fund · collab
RandomizedParallel-groupDouble-blindTreatment
Summary
This clinical trial aims to test the effects of fluvoxamine as a treatment for Long COVID. Fluvoxamine is an FDA approved SSRI for Obsessive Compulsive Disorder (OCD), that has already had success in preventing hospitalization in patients with COVID-19 (STOP COVID and TOGETHER trials). This trial is testing whether fluoxamine helps to improve symptoms and the negative impacts of long COVID in residents of Missouri and Illinois.
Timeline
- Start
- 2023-05-15
- Primary completion
- 2025-03-15
- Completion
- 2025-03-15
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Fluvoxamine | Unknown | — | — |